Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NYMX
Previous Symbol
CUSIPN/A
Phone800-936-9669
Debt
Debt-to-Equity RatioN/A
Current Ratio5.65
Quick Ratio5.62
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$220,000.00
Price / Sales457.68
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.02) per share
Price / Book-88.00
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-13,420,000.00
Net Margins-2,909.61%
Return on Equity-863.35%
Return on Assets-378.13%
Miscellaneous
EmployeesN/A
Outstanding Shares57,210,000
Market Cap$100.69 million
OptionableOptionable
Nymox Pharmaceutical (NASDAQ:NYMX) Frequently Asked Questions
What is Nymox Pharmaceutical's stock symbol?
Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."
How were Nymox Pharmaceutical's earnings last quarter?
Nymox Pharmaceutical Corp (NASDAQ:NYMX) announced its quarterly earnings results on Tuesday, November, 13th. The biopharmaceutical company reported ($0.05) EPS for the quarter. The biopharmaceutical company had revenue of $0.04 million for the quarter. Nymox Pharmaceutical had a negative return on equity of 863.35% and a negative net margin of 2,909.61%. View Nymox Pharmaceutical's Earnings History.
When is Nymox Pharmaceutical's next earnings date?
Has Nymox Pharmaceutical been receiving favorable news coverage?
News stories about NYMX stock have been trending positive this week, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nymox Pharmaceutical earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the company's share price in the next few days.
Are investors shorting Nymox Pharmaceutical?
Nymox Pharmaceutical saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 1,128,113 shares, a drop of 28.0% from the October 15th total of 1,567,137 shares. Based on an average daily volume of 199,897 shares, the short-interest ratio is currently 5.6 days. Currently, 3.3% of the company's stock are sold short. View Nymox Pharmaceutical's Current Options Chain.
Who are some of Nymox Pharmaceutical's key competitors?
Some companies that are related to Nymox Pharmaceutical include Oxford Immunotec Global (OXFD), Quotient (QTNT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Vermillion (VRML), Riot Blockchain (RIOT), Akers Biosciences (AKER), Achieve Life Sciences (ACHV), Arca Biopharma (ABIO), GeneNews (GNWSF), Fluoropharma Medical (FPMI), BG Medicine (BGMD), Response Genetics (RGDXQ) and Palatin Technologies (PTN).
Who are Nymox Pharmaceutical's key executives?
Nymox Pharmaceutical's management team includes the folowing people:
- Dr. Paul Averback, Founder, Chairman, CEO & Pres (Age 67)
- Mr. Erik Danielsen, Chief Financial Officer (Age 55)
- Mr. Randall J. Lanham, Gen. Counsel, Sec. & Director (Age 54)
- Dr. Judith Fitzpatrick Ph.D., Exec. (Age 69)
- Dr. Suresh Kalbag M.D., Director of CMC Operations
Who are Nymox Pharmaceutical's major shareholders?
Nymox Pharmaceutical's stock is owned by many different of institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.27%). Company insiders that own Nymox Pharmaceutical stock include James George Robinson, Paul Averback and Randall J Lanham. View Institutional Ownership Trends for Nymox Pharmaceutical.
Which major investors are selling Nymox Pharmaceutical stock?
How do I buy shares of Nymox Pharmaceutical?
Shares of NYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nymox Pharmaceutical's stock price today?
One share of NYMX stock can currently be purchased for approximately $1.76.
How big of a company is Nymox Pharmaceutical?
Nymox Pharmaceutical has a market capitalization of $100.69 million and generates $220,000.00 in revenue each year.
What is Nymox Pharmaceutical's official website?
How can I contact Nymox Pharmaceutical?
Nymox Pharmaceutical's mailing address is 9900 CAVENDISH BLVD. SUITE 306, ST. LAURENT A8, H4M 2V2. The biopharmaceutical company can be reached via phone at 800-936-9669 or via email at [email protected]
MarketBeat Community Rating for Nymox Pharmaceutical (NASDAQ NYMX)
MarketBeat's community ratings are surveys of what our community members think about Nymox Pharmaceutical and other stocks. Vote "Outperform" if you believe NYMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NYMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
